| Literature DB >> 34084192 |
Malihe Safari1, Hossein Mahjub2, Habib Esmaeili3, Mohammad Abbasi4, Ghodratollah Roshanaei5.
Abstract
BACKGROUND: In situation where there are more than one cause of occurring the outcome such as recurrence after surgery and death, the assumption of classical survival analyses are not satisfied. To cover this issue, this study aimed at utilizing competing risks survival analysis to assess the specific risk factors of local-distance recurrence and mortality in patients with colorectal cancer (CRC) undergoing surgery.Entities:
Keywords: Cause-specific hazard; colorectal neoplasms; competing risk; cumulative incidence; recurrence
Year: 2021 PMID: 34084192 PMCID: PMC8106405 DOI: 10.4103/jrms.JRMS_430_20
Source DB: PubMed Journal: J Res Med Sci ISSN: 1735-1995 Impact factor: 1.852
Profile of patients with colorectal cancer after resection surgery by outcome
| Variable | Category | Death, | Recurrence, | Total, | ||
|---|---|---|---|---|---|---|
| Yes | No | Yes | No | |||
| Gender | Male | 71 (52.6) | 64 (47.4) | 66 (48.9) | 69 (51.1) | 135 (53.1) |
| Female | 75 (63) | 44 (37) | 48 (40.3) | 71 (59.7) | 119 (46.9) | |
| Age at diagnosis (years) | <50 | 48 (60.8) | 31 (39.2) | 34 (43) | 45 (57) | 79 (31.1) |
| 51–70 | 84 (59.2) | 58 (40.8) | 62 (43.7) | 80 (56.3) | 142 (55.9) | |
| >70 | 14 (42.4) | 19 (57.6) | 18 (54.5) | 15 (45.5) | 33 (13) | |
| BMI (kg/m2) | <18.5 | 23 (52.3) | 21 (47.7) | 22 (50) | 22 (50) | 44 (17.3) |
| 18.5–25 | 96 (60.8) | 62 (39.2) | 67 (42.4) | 91 (57.6) | 158 (62.2) | |
| >25 | 27 (51.9) | 25 (48.1) | 25 (48.1) | 27 (51.9) | 52 (20.5) | |
| Chemoradiotherapy | Yes | 35 (51.5) | 33 (48.5) | 34 (50) | 34 (50) | 68 (26.8) |
| No | 111 (59.7) | 75 (40.3) | 80 (43) | 106 (57) | 186 (73.2) | |
| Chemotherapy | Yes | 118 (55.1) | 96 (44.9) | 102 (47.7) | 112 (52.3) | 214 (84.3) |
| No | 28 (70) | 12 (30) | 12 (30) | 28 (70) | 40 (15.7) | |
| Pathological stage | 2 | 104 (81.9) | 23 (18.1) | 28 (22) | 99 (78) | 127 (50) |
| 3 | 37 (48.1) | 40 (51.9) | 36 (46.8) | 41 (53.2) | 77 (30.3) | |
| 4 | 5 (10) | 45 (90) | 50 (100) | 0 | 50 (19.7) | |
| Tumor site | Colon | 107 (59.8) | 72 (40.2) | 81 (45.3) | 98 (54.7) | 179 (70.5) |
| Rectum | 39 (52) | 36 (58) | 33 (44) | 42 (56) | 75 (29.5) | |
| Tumor grade | Well | 68 (61.8) | 42 (38.2) | 42 (38.2) | 68 (61.8) | 110 (43.3) |
| Moderate | 70 (55.6) | 56 (44.4) | 63 (50) | 63 (50) | 126 (49.6) | |
| Poor | 8 (44.4) | 10 (55.6) | 9 (50) | 9 (50) | 18 (7.1) | |
| T stage | T2 | 30 (81.1) | 7 (18.9) | 7 (18.9) | 30 (81.1) | 37 (14.6) |
| T3 | 109 (57.7) | 80 (42.3) | 85 (45) | 104 (55) | 189 (74.4) | |
| T4 | 7 (25) | 21 (75) | 22 (78.6) | 6 (21.4) | 28 (11) | |
| N stage | N0 | 110 (71.9) | 43 (28.1) | 50 (32.7) | 103 (67.3) | 153 (60.2) |
| N1 | 33 (44.6) | 41 (55.4) | 40 (54.1) | 34 (45.9) | 74 (29.1) | |
| N2 | 3 (11.1) | 24 (88.9) | 24 (88.9) | 3 (11.1) | 27 (10.6) | |
| Tumor size (mm) | ≤5 | 100 (57.5) | 74 (42.5) | 76 (43.7) | 98 (56.3) | 174 (68.5) |
| >5 | 25 (58.1) | 18 (41.9) | 20 (46.5) | 23 (53.5) | 43 (16.9) | |
| Unknown | 21 (56.8) | 16 (43.2) | 18 (48.6) | 19 (51.4) | 37 (14.6) | |
| Recurrence | Yes | 93 (81.6) | 21 (18.4) | 114 (100) | 0 | 114 (44.9) |
| No | 15 (10.7) | 125 (89.3) | 0 | 140 (100) | 140 (55.1) | |
| Hb | Normal | 24 (63.2) | 14 (36.8) | 15 (39.5) | 23 (60.5) | 38 (15) |
| Abnormal | 35 (55.6) | 28 (44.4) | 29 (46) | 34 (54) | 63 (24.8) | |
| Unknown | 66 (43.1) | 87 (56.9) | 78 (51) | 75 (49) | 153 (60.2) | |
| WBC | Normal | 44 (56.4) | 34 (43.6) | 32 (41) | 46 (59) | 78 (30.7) |
| Abnormal | 12 (57.1) | 9 (42.9) | 13 (61.9) | 8 (38.1) | 21 (8.3) | |
| Unknown | 65 (41.9) | 90 (58.1) | 77 (49.7) | 78 (50.3) | 155 (61) | |
| PLT | Normal | 38 (55.1) | 31 (44.9) | 30 (43.5) | 39 (56.5) | 69 (27.2) |
| Abnormal | 12 (63.2) | 7 (36.9) | 11 (57.9) | 8 (42.1) | 19 (7.5) | |
| Unknown | 70 (42.2) | 96 (57.8) | 82 (49.4) | 84 (50.6) | 166 (65.3) | |
BMI=Body mass index; Hb=Hemoglobin; WBC=White blood cell; PLT=Platelets in the patient’s blood
Figure 1Kaplan–Meier estimates of overall survival according to tumor site
Results uni-and multivariable cause–specific hazard model for relation between potential risk factors and hazard of death in patients with colorectal cancer after surgery
| Variable | Category | Unadjusted HR (95% CI) | Adjusted HR (95% CI) |
|---|---|---|---|
| Gender | Male | 1 | - |
| Female | 0.66 (0.36–1.1.21) | - | |
| Age at diagnosis (years) | <50 | 1 | 1 |
| 51–70 | 1.11 (0.68–2.6)* | 1.197 (0.59–2.37) | |
| >70 | 2.835 (1.15–7.5)* | 3.15 (1.14–6.49)* | |
| BMI (kg/m2) | <18.5 | 1 | - |
| 18.5–25 | 0.75 (0.46–1.24) | - | |
| >25 | 0.82 (0.33–2.11) | - | |
| Chemoradiotherapy | Yes | 1 | - |
| No | 2.28 (0.95–3.93) | - | |
| Chemotherapy | Yes | 1 | - |
| No | 1.473 (0.58–3.73) | - | |
| Pathological stage | 2 | 1 | 1 |
| 3 | 2.69 (1.36–5.36)* | 4.28 (1.66–11.15)* | |
| 4 | 7.45 (3.41–16.29)* | 5.37 (1.75–17.46)* | |
| Tumor site | Colon | 1 | 1 |
| Rectum | 2.17 (1.21–3.91)* | 2.45 (1.32–4.41)* | |
| Tumor grade | Well | 1 | - |
| Moderate | 1.22 (0.67–2.27) | - | |
| Poor | 1.46 (0.49–4.4) | - | |
| T stage | T2 | 1 | 1 |
| T3 | 1.23 (0.49–4.72) | 1.07 (0.46–2.47) | |
| T4 | 1.93 (1.28–9.75)* | 1.01 (0.39–2.64) | |
| N stage | N0 | 1 | 1 |
| N1 | 1.65 (0.85–3.16) | 0.92 (.48–1.79) | |
| N2 | 2.96 (1.12–7.83)* | 1.81 (0.92–3.6) | |
| Recurrence | No | 1 | 1 |
| Yes | 5.11 (2.67–9.69)* | 3.92 (1.89–8.34)* | |
| Tumor size (mm) | ≤5 | 1 | - |
| <5 | 1.11 (0.56–1.57) | - | |
| Unknown | 1.25 (0.57–1.98) | - | |
| WBC | Normal | 1 | - |
| Abnormal | 0.96 (0.46–2.02) | - | |
| Hb | Normal | 1 | - |
| Abnormal | 1.04 (0.89–1.53) | - | |
| PLT | Normal | 1 | - |
| Abnormal | 1.02 (0.99–1.11) | - |
*P<0.05. HR=Hazard ratio; BMI=Body mass index; Hb=Hemoglobin; WBC=White blood cell; PLT=Platelets in the patient’s blood; CI=Confidence interval
Cumulative incidence of local/distance metastasis by potential risk factors for patients with colorectal cancer after resection surgery
| Variable | Category | Cumulative incidence (years) | ||||
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 5 | 10 | ||
| Gender | Male | 0.28 | 0.43 | 0.47 | 0.54 | 0.62 |
| Female | 0.30 | 0.38 | 0.43 | 0.47 | 0.49 | |
| Age at diagnosis | <50 | 0.24 | 0.37 | 0.42 | 0.50 | 0.55 |
| 51–70 | 0.26 | 0.37 | 0.42 | 0.48 | 0.55 | |
| >70 | 0.54 | 0.68 | 0.68 | 0.69 | 0.71 | |
| BMI | <18.5 | 0.39 | 0.53 | 0.53 | 0.57 | 0.65 |
| 18.5–25 | 0.24 | 0.34 | 0.41 | 0.48 | 0.55 | |
| >25 | 0.35 | 0.48 | 0.51 | 0.55 | 0.55 | |
| Chemoradiotherapy | Yes | 0.25 | 0.45 | 0.47 | 0.53 | 0.68 |
| No | 0.31 | 0.38 | 0.44 | 0.50 | 0.52 | |
| Chemotherapy | Yes | 0.22 | 0.26 | 0.29 | 0.34 | 0.39 |
| No | 0.30 | 0.43 | 0.47 | 0.54 | 0.59 | |
| Pathological stage | 2 | 0.08 | 0.15 | 0.18 | 0.25 | 0.37 |
| 3 | 0.28 | 0.40 | 0.47 | 0.54 | 0.56 | |
| 4 | 0.78 | 0.96 | 1.00 | 1.00 | 1.00 | |
| Tumor site | Colon | 0.31 | 0.41 | 0.47 | 0.54 | 0.55 |
| Rectum | 0.24 | 0.40 | 0.40 | 0.44 | 0.61 | |
| Tumor grade | Well | 0.26 | 0.34 | 0.39 | 0.46 | 0.48 |
| Moderate | 0.31 | 0.45 | 0.49 | 0.54 | 0.64 | |
| Poor | 0.34 | 0.46 | 0.46 | 0.53 | 0.55 | |
| T stage | T2 | 0.10 | 0.10 | 0.14 | 0.19 | 0.33 |
| T3 | 0.29 | 0.41 | 0.45 | 0.51 | 0.56 | |
| T4 | 0.50 | 0.71 | 0.76 | 0.83 | 0.91 | |
| N stage | N0 | 0.17 | 0.29 | 0.31 | 0.37 | 0.47 |
| N1 | 0.35 | 0.49 | 0.56 | 0.61 | 0.63 | |
| N2 | 0.74 | 0.78 | 0.86 | 1.00 | 1.00 | |
| Tumor size | ≤5 | 0.28 | 0.39 | 0.45 | 0.51 | 0.57 |
| >5 | 0.33 | 0.43 | 0.45 | 0.51 | 0.55 | |
| Hb | Normal | 0.17 | 0.32 | 0.35 | 0.48 | 0.48 |
| Abnormal | 0.24 | 0.39 | 0.47 | 0.52 | 0.56 | |
| WBC | Normal | 0.17 | 0.33 | 0.40 | 0.48 | 0.51 |
| Abnormal | 0.45 | 0.54 | 0.59 | 0.73 | 0.79 | |
| PLT | Normal | 0.18 | 0.35 | 0.42 | 0.51 | 0.51 |
| Abnormal | 0.44 | 0.51 | 0.59 | 0.69 | 0.79 | |
| Recurrence | Local | 0.07 | 0.13 | 0.16 | 0.19 | 0.22 |
| Distance | 0.25 | 0.34 | 0.38 | 0.42 | 0.44 | |
| Local/distance | 0.32 | 0.47 | 0.54 | 0.61 | 0.66 | |
BMI=Body mass index; Hb=Hemoglobin; WBC=White blood cell; PLT=Platelets in the patient’s blood
Results of uni- and multi-variable cause-specific regression models for potential risk factors of hazard of local/distance metastasis for patients with colorectal cancer after resection surgery
| Variable | Category | Unadjusted HR (95%CI) | Adjusted HR (95%CI) |
|---|---|---|---|
| Gender | Male | 1 | - |
| Female | 0.83 (0.57–1.23) | - | |
| Age at diagnosis (years) | <50 | 1 | 1 |
| 51–70 | 1.23 (0.76–2.02) | 1.02 (0.56–1.57) | |
| >70 | 2.01 (1.16–3.48)* | 1.46 (1.1–1.85)* | |
| BMI (kg/m2) | <18.5 | 1 | - |
| 18.5–25 | 0.75 (0.46–1.22) | - | |
| >25 | 0.95 (0.53–1.68) | - | |
| Chemoradiotherapy | Yes | 1 | - |
| No | 1.35 (0.9–2.02) | - | |
| Chemotherapy | Yes | 1 | - |
| No | 1.67 (0.92–3.04) | - | |
| Pathological stage | 2 | 1 | 1 |
| 3 | 4.32 (2.17–8.63)* | 1.55 (0.64–3.19) | |
| 4 | 11.37 (3.14–41.12)* | 7.62 (3.46–16.92)* | |
| Tumor site | Colon | 1 | - |
| Rectum | 1.35 (0.84–2.17) | - | |
| Tumor grade | Well | 1 | - |
| Moderate | 1.27 (0.86–1.88) | - | |
| Poor | 1.36 (0.66–2.8) | - | |
| T stage | T2 | 1 | 1 |
| T3 | 2.71 (1.25–5.89)* | 1.8 (1.1–4.7)* | |
| T4 | 6.48 (2.73–15.4)* | 2.7 (1.5–8.4)* | |
| N stage | N0 | 1 | - |
| N1 | 2.02 (1.33–3.1)* | 1.12 (0.47–2.76) | |
| N2 | 5.41 (3.29–8.84)* | 2.59 (1.13–6.1)* | |
| Tumor size (mm) | ≤5 | 1 | - |
| >5 | 1.05 (0.60–1.54) | - | |
| HB | Normal | 1 | 1 |
| Abnormal | 0.51 (0.29–0.92)* | 1.02 (0.66–1.58) | |
| WBC | Normal | 1 | 1 |
| Abnormal | 2.34 (1.2–4.6)* | 1.95 (1.11–3.26)* | |
| PLT | Normal | 1 | - |
| Abnormal | 1.37 (0.69–2.79) | - |
*P<0.05. HR=Hazard ratio; BMI=Body mass index; Hb=Hemoglobin; WBC=White blood cell; PLT=Platelets in the patient’s blood; CI=Confidence interval